Connect with us

Business

Braveheart Bio Shares Climb 5.50% as Its Phase 3 Heart Drug Trial Rapidly Gains Momentum Following Its IPO

Published

on

Braveheart Bio Shares Climb 5.50% as Its Phase 3 Heart

SAN FRANCISCO — Shares of Braveheart Bio Inc. rose 5.50% to $29.24 in Thursday trading, adding $1.53, as the clinical-stage cardiovascular biotechnology company continued to draw investor interest following the initiation of a pivotal late-stage trial for its lead heart disease drug candidate roughly six weeks after going public.

Braveheart Bio is developing therapies for hypertrophic cardiomyopathy, a serious cardiovascular condition in which the heart muscle grows abnormally thick, making it harder for the heart to pump blood efficiently. The company’s lead candidate, BHB-1893, is an oral, next-generation small-molecule cardiac myosin inhibitor being developed to treat both the obstructive and non-obstructive forms of the disease. Braveheart has said it designed the drug to address limitations in currently available treatments in its class, aiming for rapid onset of effect, consistent depth of response, preservation of the heart’s pumping function, prompt reversibility if treatment needs to be stopped, and a more straightforward approach to dosing and patient monitoring than existing options.

The company reported second-quarter 2026 financial results and a business update on September 8, disclosing that it had formally initiated LIONHEART-HCM, a global Phase 3 trial evaluating BHB-1893 against the beta-blocker metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy. That trial follows positive Phase 2 results in the obstructive form of the disease announced in March. Braveheart Chief Executive Officer and President Travis Murdoch, M.D., framed the milestone as validation of the company’s broader strategy following its public listing. “Our clinical programs continue to advance, and our IPO this summer has provided a strong financial foundation to advance the development of our global Phase 3 programs and evaluate the potential of BHB-1893 as the preferred treatment option in two indications,” Murdoch said. “Sites are being activated and patients are screening for our LIONHEART-HCM Phase 3 study in obstructive HCM, and we are on track to dose the first patient this year. We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027.”

Murdoch also provided an update on the company’s second target indication, the non-obstructive form of hypertrophic cardiomyopathy. “In addition, our program in non-obstructive HCM is advancing; we now have an active U.S. investigational new drug application and expect to initiate our NOBLEHEART-HCM Phase 3 study in the first half of 2027,” he said. That planned trial follows positive Phase 2 results in non-obstructive patients, developed in partnership with China’s Jiangsu Hengrui Pharmaceuticals, which were presented as a late-breaking study at the 2026 annual meeting of the Heart Failure Association of the European Society of Cardiology in May. In that trial, patients treated with BHB-1893 showed rapid, statistically significant improvements in cardiac biomarkers, functional status and exercise capacity compared with placebo, along with dose-dependent improvements in heart muscle relaxation and structure on echocardiogram, without any patients in the treatment groups requiring a dose interruption due to reduced heart pumping function, a safety concern that has affected some competing drugs in the same class.

Advertisement

Braveheart completed its initial public offering in August, issuing 24.4 million shares of common stock at $18 per share for gross proceeds of approximately $439.9 million, with the stock beginning to trade on the Nasdaq Global Market on August 6. Including the net proceeds from that offering, the company reported cash and cash equivalents of approximately $527.3 million on an as-adjusted basis as of June 30, which it said should be sufficient to fund its operating expenses and capital requirements into 2029, giving the company a lengthy runway to advance both Phase 3 programs toward potential regulatory approval without an immediate need to return to capital markets.

The company’s second-quarter financial results reflected the scale of investment required to support that expanding late-stage clinical program. Research and development expenses reached $11.1 million for the quarter, up sharply from essentially no comparable spending a year earlier, driven by the advancement of BHB-1893 and preparation for the global Phase 3 program. General and administrative expenses climbed to $4.8 million for the quarter as the company built out the operational infrastructure needed to function as a newly public company. Net loss attributable to common stockholders totaled $18.6 million for the quarter, or $2.51 per share, after accounting for a non-cash deemed dividend tied to the company’s earlier Series A preferred stock financing.

Braveheart’s stock has traded within a 52-week range of $24.31 to $32.00 since its public debut, with the company’s shares drawing a Strong Buy consensus rating from analysts covering the stock. Five analysts currently recommend buying the shares, with none recommending a sale, and the average 12-month price target sits at $45.25, implying substantial potential upside from current trading levels. Insider activity has also reflected confidence in the company’s prospects, with board director David Charles Lubner disclosed as having made an open-market purchase of more than 55,000 shares at $18 apiece in early August, shortly after the company’s public listing.

Braveheart’s backers include venture capital firm Andreessen Horowitz, which holds a significant ownership stake in the company through affiliated investment entities, according to regulatory filings disclosing beneficial ownership following the IPO.

Advertisement

With patient screening now underway for the LIONHEART-HCM trial and dosing of the first patient targeted before the end of the year, investors are likely to continue watching closely for further updates on trial enrollment progress, alongside the planned initiation of the company’s second Phase 3 program in non-obstructive hypertrophic cardiomyopathy expected in the first half of 2027, as the next major milestones likely to influence the stock’s trajectory in the months ahead.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

VICI Properties: Dirt Cheap With An Implicit 12% To 14% Total Return (NYSE:VICI)

Published

on

Bem-vindo à réplica de placas fabulosas de Las Vegas dentro da loja de souvenirs na Las Vegas Strip, Nevada, EUA

This article was written by

Hit follow for stock deep dives and long-term thesis tracking. Independent Equity Analyst tracking high-quality businesses built for multi-decade compounding. My focus is simple: identifying quality compounders, mispriced growth, and underappreciated optionalities while ignoring short-term noise. Whether evaluating mega-cap tech levers or under-the-radar global equities, I prioritize structural moats, capital allocation, and asymmetric upside. Feel free to reach out for collaborations or to connect!

Analyst’s Disclosure: I/we have a beneficial long position in the shares of VICI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Apple’s iPhone 18 goes on sale, and long lines form at stores worldwide

Published

on

Apple's iPhone 18 goes on sale, and long lines form at stores worldwide

Apple fans eager to get their hands on the latest iPhone crowded stores worldwide on Friday.

The 18 Pro and Pro Max lineup, unveiled last week at Apple’s annual event alongside its foldable phone Duo, features a reimagined camera with a DSLR-like aperture, improving performance in low-light environments and offering enhanced depth of field.

Advertisement

Apple also announced that the new line of iPhone 18s will be able to detect AI-generated photos by creating an unalterable Reference Image that lives alongside the edited one.

INSIDE JOHN TERNUS’ FIRST APPLE LAUNCH EVENT AS CEO: FOLDABLE IPHONE DUO, AI AND MORE

Apple iPhone 18 Pro lineup.

Different color phones in Apple’s iPhone 18 Pro lineup (Apple Inc.)

The iPhone 18 Pro starts at $1,199, and the iPhone 18 Pro Max starts at $1,299 with lease options through Apple Upgrade.

Apple CEO John Ternus, who succeeded Tim Cook earlier this month, visited the company’s flagship store on Fifth Avenue in New York City Friday. He posed for pictures and signed autographs for customers inside and outside the location in Midtown Manhattan.

Advertisement

APPLE UNVEILS FIRST FOLDABLE IPHONE, IPHONE 18 PRO LINEUP, NEW WATCHES AT ANNUAL LAUNCH EVENT

The new iPhone marks the launch of the new-and-improved Siri, powered by Apple Intelligence. The new Siri, called Siri AI, was announced in June but was delayed until now to make sure everything was right, according to Apple.

APPLE ENTERS A NEW ERA AS JOHN TERNUS TAKES OVER AS CEO

Advertisement

Siri AI runs on Google Gemini models and is able to perform features such as pulling information from messages, photos, emails and more. Users will also be able to draft messages and emails, edit photos and access past conversations with Siri.

Apple Store at the Menlo Park Mall in New Jersey.

People line up outside the Apple Store at the Menlo Park Mall in Edison, N.J., Sept. 18, 2026. (Fox News Digital)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Advertisement
Continue Reading

Business

Coinbase Shares Jump 11.72% as SEC’s Tokenized Stock Rule and Bitcoin Rally Fuel Broader Crypto Surge

Published

on

Coinbase

NEW YORK — Shares of Coinbase Global Inc. jumped 11.72% to $194.36 in Friday trading, adding $20.39, as the cryptocurrency exchange rode a broad rally across crypto-linked equities tied to a sharp rebound in bitcoin’s price and a new regulatory development from the Securities and Exchange Commission.

Coinbase shares extended gains that began in premarket trading, when crypto-linked stocks including Coinbase, Strategy Inc. and Robinhood Markets all advanced sharply as investors responded to the SEC’s introduction of a new exemption allowing trading of tokenized U.S. stocks, according to market commentary. The move was widely interpreted as a regulatory tailwind for exchanges like Coinbase that have positioned themselves to benefit from the broader tokenization of traditional financial assets onto blockchain infrastructure.

The rally in Coinbase shares also tracked a sharp advance in bitcoin’s own price, which traded above $80,000, up roughly 5.5% over the prior 24 hours, as investors across markets reacted favorably to the Federal Reserve’s interest rate decision earlier in the week, which signaled a less aggressive path for future rate increases than some had anticipated. That relief rally extended broadly across risk assets, with cryptocurrency and crypto-linked equities among the most direct beneficiaries given their historically close correlation with broader shifts in risk appetite.

Beyond the sector-wide rally, Coinbase also benefited from company-specific news. The exchange was named a founding brokerage partner for a new Cashtag Partner Program launched by the social media platform X, an arrangement that will allow X users to initiate stock and cryptocurrency trades directly through the platform. The partnership extends Coinbase’s reach into a large, established social media user base and reflects the company’s ongoing effort to broaden distribution for its trading and custody services beyond its own standalone app and website.

Advertisement

Sentiment toward bitcoin’s broader price trajectory has also turned notably more optimistic among some prominent crypto research analysts in recent days. Zach Pandl, head of research at Grayscale, told clients that he believes bitcoin’s June low near $58,000 marked the bottom of the current market cycle, offering what he described as a “green light” for the asset’s outlook from that point forward, according to reporting on his comments. That kind of bullish institutional commentary has added to the broader wave of positive sentiment that has lifted both bitcoin itself and the equities of companies whose businesses are closely tied to its price.

Coinbase’s own strategic positioning has increasingly emphasized the broader convergence of cryptocurrency infrastructure with both artificial intelligence and the tokenization of traditional financial assets. In investor materials, the company has described crypto as “the native execution rail for the agent-led economy,” pointing to projections that AI-native finance agents could process as much as $35 trillion in transactions by 2030. Coinbase has separately highlighted the rapid growth potential of tokenized real-world assets, an area the company has said currently represents a market of roughly $30 billion but could grow to as much as $16 trillion by 2030, alongside continued expansion of the stablecoin market, which the company has said stood at approximately $305 billion as of the first quarter of 2026 and could grow tenfold to $3 trillion by the end of the decade.

Coinbase’s total crypto trading volume across the industry has grown more than 50-fold over the past seven years, reaching roughly $14 trillion as of the first quarter of 2026, according to figures the company has cited from CoinDesk Data, CoinMetrics and Dune Analytics, underscoring the scale of growth in the broader market the company has built its business around facilitating.

The company’s leadership team includes chief executive officer and co-founder Brian Armstrong, along with a board of directors that includes venture capitalist Marc Andreessen, Coinbase co-founder Frederick Ernest Ehrsam III, and Shopify president Tobias Lütke, among others, following the company’s most recent annual shareholder meeting held in the spring. Alesia Haas serves as chief financial officer, while Emilie Choi serves as president and chief operating officer.

Advertisement

Coinbase’s stock has traded within a wide 52-week range spanning from $139.11 to $402.16, reflecting the substantial volatility that has characterized the company’s shares since its 2021 public listing, a pattern closely tied to swings in the broader cryptocurrency market the company’s revenue and trading volume depend heavily upon. That volatility has made Coinbase, alongside companies like Strategy and Robinhood, one of the more closely watched proxies for broader investor sentiment toward the cryptocurrency sector as a whole, with the stock’s price movements often amplifying shifts in bitcoin and the broader crypto market during periods of heightened trading activity.

With bitcoin’s rally continuing to build momentum and the SEC’s new tokenized securities exemption still in its early days of implementation, investors are likely to watch closely for further regulatory guidance and additional company-specific partnerships in the sessions ahead, as Coinbase and its crypto-linked peers continue positioning themselves at the center of the broader convergence between traditional finance, artificial intelligence and blockchain-based asset tokenization that has increasingly defined the sector’s growth narrative heading into the final months of the year.

Continue Reading

Business

PGIM Target Date Funds Q2 2026 Commentary

Published

on

Northern Small Cap Index Fund Q1 2026 Commentary (Mutual Fund:NSIDX)

Stacks of coins and an hourglass, image of long-term investment

takasuu/iStock via Getty Images

PGIM Target Date Funds Overview

The PGIM Target Date Funds combine PGIM’s asset management capabilities, insights into participant behavior, and Prudential’s leadership in pension risk transfer. Together, these provide us with a unique vantage point to assess the retirement

Continue Reading

Business

Troubled Australian developer Bathla granted one-year extension to complete projects

Published

on


Troubled Australian developer Bathla granted one-year extension to complete projects

Continue Reading

Business

Fiji Declares Formal National HIV Emergency as Infections Surge 12-Fold Over the Past 15 Years, UN Warns

Published

on

Taco Bell

WELLINGTON, New Zealand — Fiji has declared a national HIV emergency after new data showed an estimated one in every 60 people in the South Pacific island nation is living with the virus, prompting the government to significantly expand testing and treatment efforts as officials confront what they describe as a fast-worsening crisis.

According to the Joint United Nations Program on HIV and AIDS, new infections in Fiji have increased twelvefold over the past 15 years. The agency said approximately 9,000 people were living with HIV in the country in 2025, a striking figure for a nation with a population of fewer than one million. UNAIDS data showed that only 39% of those infected knew their HIV status, while just 22% of people living with the virus were receiving antiretroviral treatment, underscoring significant gaps in both diagnosis and care.

The scale of the shift has been particularly stark among specific population groups. Officials said one in every 60 adults in Fiji now has HIV, compared with one in 167 just five years ago. Among pregnant women specifically, the rate is even higher, with one in every 50 estimated to be living with the virus.

Fiji’s Health Minister, Antonio Lalabalavu, announced the elevated emergency designation in a video statement posted to Facebook this week, framing the move as a necessary escalation given the scale of the crisis. “This means HIV is now a national crisis and the government is treating it like one. No more business as usual,” Lalabalavu said. “More people in Fiji are living with HIV than ever before.”

Advertisement

The declaration marks a further escalation from an earlier response. Lalabalavu had designated HIV an “outbreak” in Fiji in January 2025, but said the country’s Cabinet decided this month that classification was no longer a sufficient response to the scale of the problem, prompting the shift to a formal national emergency designation. That elevated status requires government agencies across multiple sectors to coordinate directly with the health ministry in addressing the crisis, rather than treating it as a matter for health authorities alone.

Lalabalavu said part of the apparent rise in case numbers reflects expanded testing efforts reaching more of the population than in previous years, rather than new infections alone. As part of its response, the government said it is expanding access to free HIV testing and free treatment for anyone who tests positive, alongside a needle exchange program aimed at reducing transmission among people who inject drugs. Officials acknowledged, however, that stigma surrounding the illness remains a significant obstacle to getting more people tested and into care. Addressing that concern directly, Lalabalavu said the government’s approach was centered on support rather than punishment. “This is about protecting people — not judging them, not watching them, not shaming them,” he said.

Public health analysts have linked much of the recent surge to the growing use of injected methamphetamine, which has expanded rapidly across the Pacific region as drug trafficking networks increasingly use island nations as transit points for narcotics moving between larger markets. That pattern of rising injection drug use has been identified as a significant driver of new HIV transmissions in Fiji and other Pacific nations grappling with similar trends.

Fiji’s crisis fits within a broader, uneven pattern of HIV prevalence across the Pacific Islands. HIV rates have generally remained low throughout most of the region, with a notable exception in Papua New Guinea, where infections have surged dramatically since 2010, producing the highest and fastest-growing HIV case numbers in the Pacific. Papua New Guinea’s government declared its own national HIV crisis in June 2025, roughly a year before Fiji’s latest escalation.

Advertisement

Public health officials have expressed concern that even nations with historically low HIV prevalence remain vulnerable to sudden outbreaks given the region’s demographic and infrastructure challenges. Most Pacific Island nations have very small populations, and health services in many of these countries are inconsistently funded or unevenly available, conditions that can make it difficult to identify and contain the spread of the virus once transmission begins accelerating.

UNAIDS Executive Director Winnie Byanyima addressed Fiji’s situation directly in a statement, framing the country’s crisis as part of a broader global warning. “A stark reminder to the world that AIDS is not over,” Byanyima said, describing the significance of Fiji’s emergency declaration within the context of ongoing global efforts to control the HIV epidemic decades after it first emerged as a major public health threat.

With Fiji now formally treating HIV as a national emergency, the coming months are likely to bring closer scrutiny of the government’s expanded testing and treatment programs, along with continued monitoring from regional and international health bodies tracking whether the country’s response succeeds in narrowing the substantial gaps in both diagnosis and treatment access that UNAIDS data has identified as central weaknesses in the country’s response to date.

Advertisement
Continue Reading

Business

GXO Logistics options sweep points to asymmetric bullish bet through January 2027

Published

on


GXO Logistics options sweep points to asymmetric bullish bet through January 2027

Continue Reading

Business

Crowd Connected founder James Cobb

Published

on

Crowd Connected founder James Cobb

James Cobb founded Crowd Connected at the Surrey Technology Centre in Guildford in 2013, after years as a tour manager and event safety specialist. The company now has more than 400 deployments across 30 countries, working with Informa, Live Nation, Coachella, CES and PCMA. He tells Business Matters why he still hoovers the office on a Friday.

What do you currently do at Crowd Connected?

I am the founder and CEO of Crowd Connected, a location intelligence company I started in Guildford in 2013. At its simplest, we help organisations understand what people are actually doing in physical spaces.

The digital world measures everything. Every click, search and transaction leaves a trail of data. Yet a surprising amount of the physical world is still managed using assumptions, rules of thumb, booking systems and somebody’s best guess.

Free newsletters
Advertisement

The stories that matter to UK business, straight to your inbox.

Advertisement

Our technology measures things such as movement, occupancy and dwell time across events, venues, university campuses and other complex spaces. The platform handles indoor positioning, wayfinding, occupancy counting and asset tracking, and it self-calibrates rather than requiring anyone to walk a site fingerprinting it first, so it goes live in hours. We have now supported more than 400 deployments across 30 countries, including Informa events and conferences and music festivals such as Coachella and BST Hyde Park, and tracked more than 250,000 delegates.

My role has changed considerably as the company has grown, but I still spend a lot of time sitting in the gap between the technology and the customer problem. I like understanding why something works, why it does not and whether what we are building genuinely creates value.

We have deliberately remained a fairly small team. There was a time when I was slightly embarrassed about that, because startup culture can encourage you to measure success by headcount. I am not anymore. A small team forces discipline. You have to automate, build products properly and be very clear about what actually creates value. Scaling without locking into fixed costs is a live question for a lot of owner-managers, and headcount is the biggest fixed cost most of them take on.

What was the inspiration behind your business?

Before Crowd Connected I spent many years working in live events, initially as a tour and production manager and later specialising in event safety.

Advertisement

Festivals are effectively temporary cities. You plan everything in extraordinary detail, from how many people can fit into an area, to how quickly a crowd can move through an entrance, to how long it will take to empty a car park. What struck me was how little real measurement sat behind some of those plans.

I remember being challenged at a licensing hearing about where some traffic-flow figures had come from. The honest answer was that I had stood on a corner in a hi-vis jacket and counted how many cars could turn left out of a car park onto a single carriageway in ten minutes.

I simply thought there had to be a better way, so I started experimenting with technology, initially with early GPS equipment and previous-generation Bluetooth devices. At one Wembley Stadium show I strapped a Bluetooth transmitter to a handrail to see whether I could use it to estimate crowd density. That question, how do people really move through physical spaces, has effectively been my career ever since.

Crowd Connected grew out of that frustration with the gap between the plan and reality. Our early breakthrough was an Innovate UK backed proof of concept with Live Nation at Wireless Festival. The technology has changed enormously since then, but the underlying problem is much the same.

Advertisement

Who do you admire?

I admire people who are prepared to discover that they are wrong. One of our company values is “I seek to be corrected, not just validated”, and I increasingly think it is one of the hardest things to do well in business. We are all very good at collecting evidence for what we already want to believe.

I studied history and philosophy of science, so my examples are often historical. Darwin had a rule that any observation contradicting his theory had to be written down immediately, because he knew inconvenient facts fade from memory faster than convenient ones. If you do not admire him for the theory of evolution, you can admire him for that.

Closer to home, I admire people who change their position in a meeting. It is a small thing but I notice it every time.

Looking back, is there anything you would have done differently?

When I was at university, Procter and Gamble contacted me and invited me to an event to learn about its graduate programme. I could not, or more accurately would not, make the date they suggested, and rather arrogantly assumed that if they really wanted me they would work around me. They quite reasonably explained that it did not work like that, so I did not go.

Advertisement

It sounds like an incredibly small decision, because it was. I was not turning down a job. I was turning down lunch. But looking back, it was absolutely the wrong decision, made for the wrong reasons.

What I failed to understand was that an opportunity does not have to be something you want to do for the rest of your life to be worth taking. A few years inside an organisation like P and G could have taught me an enormous amount about management, strategy, finance and leadership, a lot of which I have had to learn the hard way.

What defines your way of doing business?

In live events, you very quickly learn that the plan and reality are not necessarily the same thing. In business I try to apply the same discipline: ask questions, look for evidence and pay particular attention to information that suggests you might be wrong.

I also believe quite strongly in autonomy. Earlier in my career I liked the feeling of being the person with the radio whom everybody needed in order to make a decision. I now realise that is usually evidence of a badly designed organisation. If everything has to come through one person, you have created a bottleneck, not a leader.

Advertisement

Good leadership is about creating systems, giving people responsibility and then letting them get on with it.

What advice would you give to someone starting out?

Treat opportunities as opportunities to learn rather than permanent decisions. When you are young, it is very easy to imagine that every choice closes off all the alternatives. Usually it does not. If an opportunity is going to expose you to interesting people, problems or skills for a couple of years, that can be enormously valuable even if you eventually decide it is not what you want to do.

I would also say that founding a business is considerably less glamorous than people sometimes imagine. I still hoover our office on a Friday. If you calculated my hourly rate you could probably make a convincing argument that this is economically irrational, but that slightly misses the point. In a small company nobody should think a job is beneath them.

And finally, learn to stop as well as start. Once we invest time and emotion in an idea, it becomes surprisingly difficult to walk away from it. Being willing to stop something that is not working can be every bit as important as having the confidence to begin.

Advertisement

Continue Reading

Business

SpaceX: Don’t Wait Till It Potentially Becomes The Largest AI Cloud (NASDAQ:SPCX)

Published

on

SpaceX: Pre-SpaceX-IPO Exposure Ideas, Particularly RONB

This article was written by

JR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and also by Seeking Alpha as a “Top Analyst To Follow” for Technology, Software, and Internet, as well as for Growth and GARP. I identify attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. My picks have consistently demonstrated market outperformance over time. My approach combines timely and sharp price action analysis with fundamentals as my foundation. I also tend to avoid overhyped and overvalued stocks while capitalizing on battered stocks with significant upside recovery possibilities. I run the investing group Ultimate Growth Investing which specializes in identifying high-potential opportunities across various sectors. My main ideas revolve around stocks with strong growth potential, and also well-beaten contrarian plays. I designed the group for investors seeking to capitalize on growth stocks with solid fundamentals, robust buying momentum, and appealing turnaround plays to generate alpha consistently. Learn more

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Enova International: Oversold, Upgrading To Buy

Published

on

Upstart: Undervalued Ahead Of A Likely Earnings Beat (NASDAQ:UPST)

Enova International: Oversold, Upgrading To Buy

Continue Reading

Trending

Copyright © 2025